JP2020523037A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020523037A5 JP2020523037A5 JP2020518110A JP2020518110A JP2020523037A5 JP 2020523037 A5 JP2020523037 A5 JP 2020523037A5 JP 2020518110 A JP2020518110 A JP 2020518110A JP 2020518110 A JP2020518110 A JP 2020518110A JP 2020523037 A5 JP2020523037 A5 JP 2020523037A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- mouse
- human
- cell
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims description 419
- 108090000623 proteins and genes Proteins 0.000 claims description 120
- 210000000130 stem cell Anatomy 0.000 claims description 102
- 108700019146 Transgenes Proteins 0.000 claims description 90
- 102000004169 proteins and genes Human genes 0.000 claims description 60
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 53
- 230000001939 inductive effect Effects 0.000 claims description 52
- 230000014509 gene expression Effects 0.000 claims description 48
- 239000003814 drug Substances 0.000 claims description 44
- 229940124597 therapeutic agent Drugs 0.000 claims description 42
- 101100494961 Mus musculus Ccl21b gene Proteins 0.000 claims description 39
- 241000700605 Viruses Species 0.000 claims description 39
- 101000638161 Homo sapiens Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 claims description 38
- 201000010099 disease Diseases 0.000 claims description 38
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 38
- 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 claims description 37
- 108010024164 HLA-G Antigens Proteins 0.000 claims description 36
- 239000012190 activator Substances 0.000 claims description 35
- 239000000411 inducer Substances 0.000 claims description 34
- -1 hydroxychloroquin Chemical compound 0.000 claims description 32
- 102000008096 B7-H1 Antigen Human genes 0.000 claims description 29
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 29
- 102100025517 Serpin B9 Human genes 0.000 claims description 29
- 230000000735 allogeneic effect Effects 0.000 claims description 28
- 238000012239 gene modification Methods 0.000 claims description 28
- 230000035755 proliferation Effects 0.000 claims description 24
- 239000003550 marker Substances 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 23
- 241000701022 Cytomegalovirus Species 0.000 claims description 20
- 206010028980 Neoplasm Diseases 0.000 claims description 20
- 230000002401 inhibitory effect Effects 0.000 claims description 19
- 239000000556 agonist Substances 0.000 claims description 17
- 210000001519 tissue Anatomy 0.000 claims description 17
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 16
- 229940088597 hormone Drugs 0.000 claims description 16
- 239000005556 hormone Substances 0.000 claims description 16
- 210000000265 leukocyte Anatomy 0.000 claims description 16
- 210000001778 pluripotent stem cell Anatomy 0.000 claims description 16
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 15
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 15
- 239000000126 substance Substances 0.000 claims description 15
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 15
- 239000003112 inhibitor Substances 0.000 claims description 14
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 14
- 230000004663 cell proliferation Effects 0.000 claims description 13
- 230000032823 cell division Effects 0.000 claims description 12
- 230000005017 genetic modification Effects 0.000 claims description 12
- 235000013617 genetically modified food Nutrition 0.000 claims description 12
- 230000001506 immunosuppresive effect Effects 0.000 claims description 12
- 210000004379 membrane Anatomy 0.000 claims description 12
- 239000012528 membrane Substances 0.000 claims description 12
- 208000024827 Alzheimer disease Diseases 0.000 claims description 11
- 102000004190 Enzymes Human genes 0.000 claims description 11
- 108090000790 Enzymes Proteins 0.000 claims description 11
- 208000023105 Huntington disease Diseases 0.000 claims description 11
- 208000018737 Parkinson disease Diseases 0.000 claims description 11
- 201000011510 cancer Diseases 0.000 claims description 11
- 150000001875 compounds Chemical class 0.000 claims description 11
- 230000007812 deficiency Effects 0.000 claims description 11
- 208000016097 disease of metabolism Diseases 0.000 claims description 11
- 208000030159 metabolic disease Diseases 0.000 claims description 11
- 201000006417 multiple sclerosis Diseases 0.000 claims description 11
- 208000010125 myocardial infarction Diseases 0.000 claims description 11
- 208000020431 spinal cord injury Diseases 0.000 claims description 11
- 101100321817 Human parvovirus B19 (strain HV) 7.5K gene Proteins 0.000 claims description 10
- 206010062016 Immunosuppression Diseases 0.000 claims description 10
- 241000713333 Mouse mammary tumor virus Species 0.000 claims description 10
- 241001494479 Pecora Species 0.000 claims description 10
- 241000700618 Vaccinia virus Species 0.000 claims description 10
- 210000004504 adult stem cell Anatomy 0.000 claims description 10
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims description 10
- 230000012010 growth Effects 0.000 claims description 10
- 210000002510 keratinocyte Anatomy 0.000 claims description 10
- 210000004072 lung Anatomy 0.000 claims description 10
- 230000002107 myocardial effect Effects 0.000 claims description 10
- 210000002437 synoviocyte Anatomy 0.000 claims description 10
- 241000701161 unidentified adenovirus Species 0.000 claims description 10
- 108020004414 DNA Proteins 0.000 claims description 9
- 229940123907 Disease modifying antirheumatic drug Drugs 0.000 claims description 9
- 206010039491 Sarcoma Diseases 0.000 claims description 9
- 210000003321 cartilage cell Anatomy 0.000 claims description 9
- 239000002988 disease modifying antirheumatic drug Substances 0.000 claims description 9
- 230000006698 induction Effects 0.000 claims description 9
- 238000002054 transplantation Methods 0.000 claims description 9
- 208000023275 Autoimmune disease Diseases 0.000 claims description 8
- 201000004569 Blindness Diseases 0.000 claims description 8
- 208000019838 Blood disease Diseases 0.000 claims description 8
- 208000031220 Hemophilia Diseases 0.000 claims description 8
- 208000009292 Hemophilia A Diseases 0.000 claims description 8
- 208000032578 Inherited retinal disease Diseases 0.000 claims description 8
- 208000019693 Lung disease Diseases 0.000 claims description 8
- 208000032430 Retinal dystrophy Diseases 0.000 claims description 8
- 208000006011 Stroke Diseases 0.000 claims description 8
- 238000002679 ablation Methods 0.000 claims description 8
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 8
- 206010003246 arthritis Diseases 0.000 claims description 8
- 230000033228 biological regulation Effects 0.000 claims description 8
- 230000007850 degeneration Effects 0.000 claims description 8
- 206010012601 diabetes mellitus Diseases 0.000 claims description 8
- 238000006471 dimerization reaction Methods 0.000 claims description 8
- 201000006321 fundus dystrophy Diseases 0.000 claims description 8
- 208000014951 hematologic disease Diseases 0.000 claims description 8
- 208000018706 hematopoietic system disease Diseases 0.000 claims description 8
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims description 8
- 208000015181 infectious disease Diseases 0.000 claims description 8
- 208000017532 inherited retinal dystrophy Diseases 0.000 claims description 8
- 208000028867 ischemia Diseases 0.000 claims description 8
- 239000003446 ligand Substances 0.000 claims description 8
- 230000007246 mechanism Effects 0.000 claims description 8
- 210000004498 neuroglial cell Anatomy 0.000 claims description 8
- 210000002569 neuron Anatomy 0.000 claims description 8
- 230000002441 reversible effect Effects 0.000 claims description 8
- UPEZCKBFRMILAV-JNEQICEOSA-N Ecdysone Natural products O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)([C@H]([C@H]([C@@H](O)CCC(O)(C)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2 UPEZCKBFRMILAV-JNEQICEOSA-N 0.000 claims description 7
- UPEZCKBFRMILAV-UHFFFAOYSA-N alpha-Ecdysone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C(O)CCC(C)(C)O)C)CCC33O)C)C3=CC(=O)C21 UPEZCKBFRMILAV-UHFFFAOYSA-N 0.000 claims description 7
- UPEZCKBFRMILAV-JMZLNJERSA-N ecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@H]([C@H](O)CCC(C)(C)O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 UPEZCKBFRMILAV-JMZLNJERSA-N 0.000 claims description 7
- 210000002540 macrophage Anatomy 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 7
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 6
- 229930105110 Cyclosporin A Natural products 0.000 claims description 6
- 108010036949 Cyclosporine Proteins 0.000 claims description 6
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 claims description 6
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 6
- 108091000080 Phosphotransferase Proteins 0.000 claims description 6
- 229960002964 adalimumab Drugs 0.000 claims description 6
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims description 6
- 239000002876 beta blocker Substances 0.000 claims description 6
- 229940097320 beta blocking agent Drugs 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 210000001185 bone marrow Anatomy 0.000 claims description 6
- 210000001612 chondrocyte Anatomy 0.000 claims description 6
- 229960001265 ciclosporin Drugs 0.000 claims description 6
- 239000003246 corticosteroid Substances 0.000 claims description 6
- 239000002532 enzyme inhibitor Substances 0.000 claims description 6
- 229940125532 enzyme inhibitor Drugs 0.000 claims description 6
- 229960002963 ganciclovir Drugs 0.000 claims description 6
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 claims description 6
- 210000004602 germ cell Anatomy 0.000 claims description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 6
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 6
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 6
- 239000002777 nucleoside Chemical class 0.000 claims description 6
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 6
- 102000020233 phosphotransferase Human genes 0.000 claims description 6
- 238000010839 reverse transcription Methods 0.000 claims description 6
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 6
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 claims description 6
- 229960001940 sulfasalazine Drugs 0.000 claims description 6
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 claims description 6
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims description 6
- 229940104230 thymidine Drugs 0.000 claims description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
- 102000008873 Angiotensin II receptor Human genes 0.000 claims description 5
- 108050000824 Angiotensin II receptor Proteins 0.000 claims description 5
- 102100032857 Cyclin-dependent kinase 1 Human genes 0.000 claims description 5
- 101710106279 Cyclin-dependent kinase 1 Proteins 0.000 claims description 5
- 101150115146 EEF2 gene Proteins 0.000 claims description 5
- 208000009889 Herpes Simplex Diseases 0.000 claims description 5
- 101001098352 Homo sapiens OX-2 membrane glycoprotein Proteins 0.000 claims description 5
- 102100037589 OX-2 membrane glycoprotein Human genes 0.000 claims description 5
- 108091027981 Response element Proteins 0.000 claims description 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 5
- 239000004098 Tetracycline Substances 0.000 claims description 5
- 230000004913 activation Effects 0.000 claims description 5
- 210000001789 adipocyte Anatomy 0.000 claims description 5
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 5
- 210000000013 bile duct Anatomy 0.000 claims description 5
- 210000000601 blood cell Anatomy 0.000 claims description 5
- 210000000988 bone and bone Anatomy 0.000 claims description 5
- 210000002449 bone cell Anatomy 0.000 claims description 5
- 210000004556 brain Anatomy 0.000 claims description 5
- 210000001593 brown adipocyte Anatomy 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 5
- 230000002124 endocrine Effects 0.000 claims description 5
- 210000002889 endothelial cell Anatomy 0.000 claims description 5
- 230000003511 endothelial effect Effects 0.000 claims description 5
- 210000002919 epithelial cell Anatomy 0.000 claims description 5
- 210000003999 epithelial cell of bile duct Anatomy 0.000 claims description 5
- 210000002907 exocrine cell Anatomy 0.000 claims description 5
- 210000004700 fetal blood Anatomy 0.000 claims description 5
- 210000002950 fibroblast Anatomy 0.000 claims description 5
- 238000010362 genome editing Methods 0.000 claims description 5
- 210000003780 hair follicle Anatomy 0.000 claims description 5
- 210000002216 heart Anatomy 0.000 claims description 5
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 5
- 210000003494 hepatocyte Anatomy 0.000 claims description 5
- 210000004966 intestinal stem cell Anatomy 0.000 claims description 5
- 210000000936 intestine Anatomy 0.000 claims description 5
- 210000003734 kidney Anatomy 0.000 claims description 5
- 208000032839 leukemia Diseases 0.000 claims description 5
- 210000004523 ligament cell Anatomy 0.000 claims description 5
- 210000004185 liver Anatomy 0.000 claims description 5
- 230000005499 meniscus Effects 0.000 claims description 5
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 5
- 210000003098 myoblast Anatomy 0.000 claims description 5
- 210000000496 pancreas Anatomy 0.000 claims description 5
- 210000000134 pericardial cell Anatomy 0.000 claims description 5
- 210000002826 placenta Anatomy 0.000 claims description 5
- 230000002285 radioactive effect Effects 0.000 claims description 5
- 230000003248 secreting effect Effects 0.000 claims description 5
- 210000003728 serous cell Anatomy 0.000 claims description 5
- 210000002363 skeletal muscle cell Anatomy 0.000 claims description 5
- 210000003491 skin Anatomy 0.000 claims description 5
- 210000000329 smooth muscle myocyte Anatomy 0.000 claims description 5
- 210000001082 somatic cell Anatomy 0.000 claims description 5
- 210000001988 somatic stem cell Anatomy 0.000 claims description 5
- 210000002325 somatostatin-secreting cell Anatomy 0.000 claims description 5
- 210000000278 spinal cord Anatomy 0.000 claims description 5
- 210000000952 spleen Anatomy 0.000 claims description 5
- 210000002784 stomach Anatomy 0.000 claims description 5
- 210000002435 tendon Anatomy 0.000 claims description 5
- 229960002180 tetracycline Drugs 0.000 claims description 5
- 229930101283 tetracycline Natural products 0.000 claims description 5
- 235000019364 tetracycline Nutrition 0.000 claims description 5
- 150000003522 tetracyclines Chemical class 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 210000003932 urinary bladder Anatomy 0.000 claims description 5
- 210000000636 white adipocyte Anatomy 0.000 claims description 5
- 229940100389 Sulfonylurea Drugs 0.000 claims description 4
- 239000012620 biological material Substances 0.000 claims description 4
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims description 3
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 claims description 3
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical class COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 claims description 3
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 claims description 3
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 claims description 3
- 239000005541 ACE inhibitor Substances 0.000 claims description 3
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 3
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 claims description 3
- 229940123208 Biguanide Drugs 0.000 claims description 3
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims description 3
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims description 3
- 229940127291 Calcium channel antagonist Drugs 0.000 claims description 3
- 102000013392 Carboxylesterase Human genes 0.000 claims description 3
- 108010051152 Carboxylesterase Proteins 0.000 claims description 3
- 102000011682 Centromere Protein A Human genes 0.000 claims description 3
- 108010076303 Centromere Protein A Proteins 0.000 claims description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 3
- 230000004543 DNA replication Effects 0.000 claims description 3
- 102100033587 DNA topoisomerase 2-alpha Human genes 0.000 claims description 3
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 claims description 3
- 208000027219 Deficiency disease Diseases 0.000 claims description 3
- 241000208011 Digitalis Species 0.000 claims description 3
- 102100031334 Elongation factor 2 Human genes 0.000 claims description 3
- 108010008165 Etanercept Proteins 0.000 claims description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Natural products OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 3
- 108010072051 Glatiramer Acetate Proteins 0.000 claims description 3
- 206010020843 Hyperthermia Diseases 0.000 claims description 3
- 108090001061 Insulin Proteins 0.000 claims description 3
- 102000003996 Interferon-beta Human genes 0.000 claims description 3
- 108090000467 Interferon-beta Proteins 0.000 claims description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 3
- 229940122048 Leucotriene receptor antagonist Drugs 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 3
- 102000010909 Monoamine Oxidase Human genes 0.000 claims description 3
- 108010062431 Monoamine oxidase Proteins 0.000 claims description 3
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims description 3
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims description 3
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 claims description 3
- 108010002687 Survivin Proteins 0.000 claims description 3
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims description 3
- 229940123464 Thiazolidinedione Drugs 0.000 claims description 3
- 239000004012 Tofacitinib Substances 0.000 claims description 3
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 claims description 3
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 claims description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 3
- 229960000548 alemtuzumab Drugs 0.000 claims description 3
- 239000002160 alpha blocker Substances 0.000 claims description 3
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims description 3
- 229940124308 alpha-adrenoreceptor antagonist Drugs 0.000 claims description 3
- 229940113720 aminosalicylate Drugs 0.000 claims description 3
- 239000002269 analeptic agent Substances 0.000 claims description 3
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 230000000844 anti-bacterial effect Effects 0.000 claims description 3
- 230000000843 anti-fungal effect Effects 0.000 claims description 3
- 230000001387 anti-histamine Effects 0.000 claims description 3
- 230000002141 anti-parasite Effects 0.000 claims description 3
- 230000000840 anti-viral effect Effects 0.000 claims description 3
- 229940088710 antibiotic agent Drugs 0.000 claims description 3
- 239000003146 anticoagulant agent Substances 0.000 claims description 3
- 229940127219 anticoagulant drug Drugs 0.000 claims description 3
- 229940121375 antifungal agent Drugs 0.000 claims description 3
- 239000000739 antihistaminic agent Substances 0.000 claims description 3
- 239000003096 antiparasitic agent Chemical class 0.000 claims description 3
- 150000004283 biguanides Chemical class 0.000 claims description 3
- 239000003613 bile acid Substances 0.000 claims description 3
- 239000003124 biologic agent Substances 0.000 claims description 3
- 230000008512 biological response Effects 0.000 claims description 3
- 239000003114 blood coagulation factor Substances 0.000 claims description 3
- 239000000480 calcium channel blocker Substances 0.000 claims description 3
- 229940022399 cancer vaccine Drugs 0.000 claims description 3
- 230000000747 cardiac effect Effects 0.000 claims description 3
- 210000004413 cardiac myocyte Anatomy 0.000 claims description 3
- 239000003543 catechol methyltransferase inhibitor Substances 0.000 claims description 3
- 230000022131 cell cycle Effects 0.000 claims description 3
- 238000002659 cell therapy Methods 0.000 claims description 3
- 230000001906 cholesterol absorption Effects 0.000 claims description 3
- 239000000812 cholinergic antagonist Substances 0.000 claims description 3
- 239000005515 coenzyme Substances 0.000 claims description 3
- 238000000315 cryotherapy Methods 0.000 claims description 3
- 229960004397 cyclophosphamide Drugs 0.000 claims description 3
- 229930182912 cyclosporin Natural products 0.000 claims description 3
- 229960004281 desmopressin Drugs 0.000 claims description 3
- NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 claims description 3
- 238000000502 dialysis Methods 0.000 claims description 3
- 230000037213 diet Effects 0.000 claims description 3
- 235000005911 diet Nutrition 0.000 claims description 3
- LDCRTTXIJACKKU-ONEGZZNKSA-N dimethyl fumarate Chemical compound COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 claims description 3
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 claims description 3
- 239000002934 diuretic Substances 0.000 claims description 3
- 229940030606 diuretics Drugs 0.000 claims description 3
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims description 3
- 238000002641 enzyme replacement therapy Methods 0.000 claims description 3
- 229960000403 etanercept Drugs 0.000 claims description 3
- 239000001530 fumaric acid Substances 0.000 claims description 3
- 229960003776 glatiramer acetate Drugs 0.000 claims description 3
- 229960001743 golimumab Drugs 0.000 claims description 3
- 230000036031 hyperthermia Effects 0.000 claims description 3
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 3
- 230000001861 immunosuppressant effect Effects 0.000 claims description 3
- 239000003018 immunosuppressive agent Substances 0.000 claims description 3
- 229940125396 insulin Drugs 0.000 claims description 3
- 229960004768 irinotecan Drugs 0.000 claims description 3
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 3
- 229960000681 leflunomide Drugs 0.000 claims description 3
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims description 3
- 229960004502 levodopa Drugs 0.000 claims description 3
- 229940127212 long-acting beta 2 agonist Drugs 0.000 claims description 3
- 239000011159 matrix material Substances 0.000 claims description 3
- 229950004994 meglitinide Drugs 0.000 claims description 3
- 230000002503 metabolic effect Effects 0.000 claims description 3
- 229960000485 methotrexate Drugs 0.000 claims description 3
- 229960004584 methylprednisolone Drugs 0.000 claims description 3
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 claims description 3
- 229960001156 mitoxantrone Drugs 0.000 claims description 3
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 3
- 239000003607 modifier Substances 0.000 claims description 3
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 claims description 3
- 229960005027 natalizumab Drugs 0.000 claims description 3
- 229960003512 nicotinic acid Drugs 0.000 claims description 3
- 239000011664 nicotinic acid Substances 0.000 claims description 3
- 235000001968 nicotinic acid Nutrition 0.000 claims description 3
- 210000000056 organ Anatomy 0.000 claims description 3
- 206010033675 panniculitis Diseases 0.000 claims description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 3
- 230000010412 perfusion Effects 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 210000000608 photoreceptor cell Anatomy 0.000 claims description 3
- 238000000554 physical therapy Methods 0.000 claims description 3
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 3
- 229960005205 prednisolone Drugs 0.000 claims description 3
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000003755 preservative agent Substances 0.000 claims description 3
- 239000006041 probiotic Substances 0.000 claims description 3
- 230000000529 probiotic effect Effects 0.000 claims description 3
- 235000018291 probiotics Nutrition 0.000 claims description 3
- 230000022558 protein metabolic process Effects 0.000 claims description 3
- 238000001959 radiotherapy Methods 0.000 claims description 3
- 229960003876 ranibizumab Drugs 0.000 claims description 3
- 238000002271 resection Methods 0.000 claims description 3
- 150000004492 retinoid derivatives Chemical class 0.000 claims description 3
- 229960004889 salicylic acid Drugs 0.000 claims description 3
- 238000010254 subcutaneous injection Methods 0.000 claims description 3
- 239000007929 subcutaneous injection Substances 0.000 claims description 3
- 210000004304 subcutaneous tissue Anatomy 0.000 claims description 3
- 238000006467 substitution reaction Methods 0.000 claims description 3
- 229960000331 teriflunomide Drugs 0.000 claims description 3
- UTNUDOFZCWSZMS-YFHOEESVSA-N teriflunomide Chemical compound C\C(O)=C(/C#N)C(=O)NC1=CC=C(C(F)(F)F)C=C1 UTNUDOFZCWSZMS-YFHOEESVSA-N 0.000 claims description 3
- 229960000278 theophylline Drugs 0.000 claims description 3
- 229960003087 tioguanine Drugs 0.000 claims description 3
- 229960001350 tofacitinib Drugs 0.000 claims description 3
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 claims description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 3
- 230000035897 transcription Effects 0.000 claims description 3
- 238000013518 transcription Methods 0.000 claims description 3
- 230000014616 translation Effects 0.000 claims description 3
- 229940124549 vasodilator Drugs 0.000 claims description 3
- 239000003071 vasodilator agent Substances 0.000 claims description 3
- 102000000311 Cytosine Deaminase Human genes 0.000 claims description 2
- 108010080611 Cytosine Deaminase Proteins 0.000 claims description 2
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 claims description 2
- 238000010322 bone marrow transplantation Methods 0.000 claims description 2
- 230000000368 destabilizing effect Effects 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 claims description 2
- 101000713085 Homo sapiens C-C motif chemokine 21 Proteins 0.000 claims 9
- 101001034314 Homo sapiens Lactadherin Proteins 0.000 claims 9
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims 9
- 101000836075 Homo sapiens Serpin B9 Proteins 0.000 claims 9
- 101100135227 Mus musculus Cd200 gene Proteins 0.000 claims 9
- 101100059528 Mus musculus Cd47 gene Proteins 0.000 claims 9
- 101100076830 Mus musculus Mfge8 gene Proteins 0.000 claims 9
- 101000638240 Mus musculus Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 claims 9
- 102000053535 human FASLG Human genes 0.000 claims 9
- 108700035927 mouse Serpinb9 Proteins 0.000 claims 9
- 101100135226 Homo sapiens CD200 gene Proteins 0.000 claims 8
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims 8
- 102000043711 human CCL21 Human genes 0.000 claims 8
- 102000048776 human CD274 Human genes 0.000 claims 8
- 102000044459 human CD47 Human genes 0.000 claims 8
- 102000051386 human MFGE8 Human genes 0.000 claims 8
- 102000046606 human SERPINB9 Human genes 0.000 claims 8
- 239000002243 precursor Substances 0.000 claims 6
- 241000714474 Rous sarcoma virus Species 0.000 claims 3
- 102100022464 5'-nucleotidase Human genes 0.000 claims 2
- 102100022718 Atypical chemokine receptor 2 Human genes 0.000 claims 2
- 102100029722 Ectonucleoside triphosphate diphosphohydrolase 1 Human genes 0.000 claims 2
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 claims 2
- 101000678892 Homo sapiens Atypical chemokine receptor 2 Proteins 0.000 claims 2
- 101001012447 Homo sapiens Ectonucleoside triphosphate diphosphohydrolase 1 Proteins 0.000 claims 2
- 101001076422 Homo sapiens Interleukin-1 receptor type 2 Proteins 0.000 claims 2
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims 2
- 102100026017 Interleukin-1 receptor type 2 Human genes 0.000 claims 2
- 102000017578 LAG3 Human genes 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 claims 1
- 102000005862 Angiotensin II Human genes 0.000 claims 1
- 101800000733 Angiotensin-2 Proteins 0.000 claims 1
- 102100036846 C-C motif chemokine 21 Human genes 0.000 claims 1
- 102100039104 Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit DAD1 Human genes 0.000 claims 1
- 229940123611 Genome editing Drugs 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 101000884921 Homo sapiens Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit DAD1 Proteins 0.000 claims 1
- 241000519695 Ilex integra Species 0.000 claims 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 1
- 102100023915 Insulin Human genes 0.000 claims 1
- 102100039648 Lactadherin Human genes 0.000 claims 1
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims 1
- 241000700584 Simplexvirus Species 0.000 claims 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 229950006323 angiotensin ii Drugs 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 229940107161 cholesterol Drugs 0.000 claims 1
- 229960004419 dimethyl fumarate Drugs 0.000 claims 1
- 229940052760 dopamine agonists Drugs 0.000 claims 1
- 230000002349 favourable effect Effects 0.000 claims 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 1
- 229960000598 infliximab Drugs 0.000 claims 1
- 210000004216 mammary stem cell Anatomy 0.000 claims 1
- 229940014456 mycophenolate Drugs 0.000 claims 1
- 210000001178 neural stem cell Anatomy 0.000 claims 1
- 230000000649 photocoagulation Effects 0.000 claims 1
- 238000002428 photodynamic therapy Methods 0.000 claims 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims 1
- 150000001467 thiazolidinediones Chemical class 0.000 claims 1
- 238000000034 method Methods 0.000 description 125
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 58
- 108010039471 Fas Ligand Protein Proteins 0.000 description 29
- 101150084532 CD47 gene Proteins 0.000 description 28
- 101150105660 MFGE8 gene Proteins 0.000 description 28
- 101710156153 Serpin B9 Proteins 0.000 description 28
- 101150059225 Cd200 gene Proteins 0.000 description 24
- 101150030213 Lag3 gene Proteins 0.000 description 11
- 230000001276 controlling effect Effects 0.000 description 11
- 101150037150 DAD1 gene Proteins 0.000 description 8
- 101150117736 Entpd1 gene Proteins 0.000 description 8
- 101100153523 Mus musculus Tnfrsf22 gene Proteins 0.000 description 7
- 210000000481 breast Anatomy 0.000 description 6
- 208000035473 Communicable disease Diseases 0.000 description 5
- 101150079765 Ackr2 gene Proteins 0.000 description 4
- 101150012716 CDK1 gene Proteins 0.000 description 4
- 101150111528 IL1R2 gene Proteins 0.000 description 4
- 229940127218 antiplatelet drug Drugs 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 210000003979 eosinophil Anatomy 0.000 description 4
- 239000007943 implant Substances 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 2
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 2
- 101150115284 BIRC5 gene Proteins 0.000 description 2
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 2
- 229940099362 Catechol O methyltransferase inhibitor Drugs 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 239000003529 anticholesteremic agent Substances 0.000 description 2
- 229940127226 anticholesterol agent Drugs 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000001461 cytolytic effect Effects 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000000925 erythroid effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000001631 haemodialysis Methods 0.000 description 2
- 230000000322 hemodialysis Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000002101 lytic effect Effects 0.000 description 2
- 210000005075 mammary gland Anatomy 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229960000951 mycophenolic acid Drugs 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 229940127211 short-acting beta 2 agonist Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000588 tumorigenic Toxicity 0.000 description 2
- 230000000381 tumorigenic effect Effects 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 101100395318 Homo sapiens HLA-G gene Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 1
- 229960004413 flucytosine Drugs 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 229960004171 hydroxychloroquine Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- UQRORFVVSGFNRO-UTINFBMNSA-N miglustat Chemical compound CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO UQRORFVVSGFNRO-UTINFBMNSA-N 0.000 description 1
- 229960001512 miglustat Drugs 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000000565 sealant Substances 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023197046A JP7724834B2 (ja) | 2017-06-12 | 2023-11-21 | 全身免疫抑制を必要としない同種免疫寛容 |
| JP2025130460A JP2025163187A (ja) | 2017-06-12 | 2025-08-05 | 全身免疫抑制を必要としない同種免疫寛容 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762518151P | 2017-06-12 | 2017-06-12 | |
| US62/518,151 | 2017-06-12 | ||
| US201862666626P | 2018-05-03 | 2018-05-03 | |
| US62/666,626 | 2018-05-03 | ||
| PCT/CA2018/050706 WO2018227286A1 (en) | 2017-06-12 | 2018-06-12 | Allograft tolerance without the need for systemic immune suppression |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023197046A Division JP7724834B2 (ja) | 2017-06-12 | 2023-11-21 | 全身免疫抑制を必要としない同種免疫寛容 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020523037A JP2020523037A (ja) | 2020-08-06 |
| JP2020523037A5 true JP2020523037A5 (https=) | 2021-08-12 |
| JP7391016B2 JP7391016B2 (ja) | 2023-12-04 |
Family
ID=64658770
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020518110A Active JP7391016B2 (ja) | 2017-06-12 | 2018-06-12 | 全身免疫抑制を必要としない同種免疫寛容 |
| JP2023197046A Active JP7724834B2 (ja) | 2017-06-12 | 2023-11-21 | 全身免疫抑制を必要としない同種免疫寛容 |
| JP2025130460A Pending JP2025163187A (ja) | 2017-06-12 | 2025-08-05 | 全身免疫抑制を必要としない同種免疫寛容 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023197046A Active JP7724834B2 (ja) | 2017-06-12 | 2023-11-21 | 全身免疫抑制を必要としない同種免疫寛容 |
| JP2025130460A Pending JP2025163187A (ja) | 2017-06-12 | 2025-08-05 | 全身免疫抑制を必要としない同種免疫寛容 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20210161971A1 (https=) |
| EP (1) | EP3638258A4 (https=) |
| JP (3) | JP7391016B2 (https=) |
| KR (2) | KR102738427B1 (https=) |
| CN (2) | CN120041380A (https=) |
| AU (3) | AU2018285972B2 (https=) |
| CA (1) | CA3064297A1 (https=) |
| GB (1) | GB2588249B (https=) |
| IL (2) | IL270835B2 (https=) |
| WO (1) | WO2018227286A1 (https=) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| WO2015105955A1 (en) | 2014-01-08 | 2015-07-16 | Flodesign Sonics, Inc. | Acoustophoresis device with dual acoustophoretic chamber |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| CN107921148A (zh) | 2015-05-08 | 2018-04-17 | 哈佛学院校长同事会 | 通用供体干细胞和相关方法 |
| KR102439221B1 (ko) | 2017-12-14 | 2022-09-01 | 프로디자인 소닉스, 인크. | 음향 트랜스듀서 구동기 및 제어기 |
| JP2021509812A (ja) | 2018-01-05 | 2021-04-08 | プレートレット バイオジェネシス， インコーポレイテッド | 巨核球を産生するための組成物および方法 |
| EP3813853A4 (en) | 2018-06-29 | 2022-04-06 | Platelet Biogenesis, Inc. | DELIVERY COMPOSITIONS AND METHODS OF USE |
| US12378572B2 (en) | 2018-09-07 | 2025-08-05 | Crispr Therapeutics Ag | Universal donor cells |
| US20220016181A1 (en) * | 2018-12-13 | 2022-01-20 | Sinai Health System | Immunomodulatory cells and uses thereof |
| JP7628499B2 (ja) * | 2019-02-27 | 2025-02-10 | 武田薬品工業株式会社 | 同種異系療法のための改良された幹細胞集団 |
| CN110179824A (zh) * | 2019-04-01 | 2019-08-30 | 普米斯生物技术(珠海)有限公司 | 一种通过免疫调控治疗ii型糖尿病的新方法 |
| US12221622B2 (en) | 2019-05-10 | 2025-02-11 | The Regents Of The University Of California | Modified pluripotent cells |
| US11162079B2 (en) | 2019-05-10 | 2021-11-02 | The Regents Of The University Of California | Blood type O Rh-hypo-immunogenic pluripotent cells |
| EP3886946A1 (en) | 2019-06-05 | 2021-10-06 | Regeneron Pharmaceuticals, Inc. | Devices and methods for precision dose delivery |
| US20220307013A1 (en) * | 2019-08-30 | 2022-09-29 | The Regents Of The University Of California | Gene fragment overexpression screening methodologies, and uses thereof |
| PH12022550542A1 (en) | 2019-09-05 | 2023-03-20 | Crispr Therapeutics Ag | Universal donor cells |
| WO2021146222A1 (en) | 2020-01-13 | 2021-07-22 | Sana Biotechnology, Inc. | Modification of blood type antigens |
| WO2021163451A1 (en) * | 2020-02-14 | 2021-08-19 | Asklepios Biopharmaceutical, Inc. | Method of treating gene therapy associated toxicity with antibiotics |
| CN115335087A (zh) * | 2020-04-01 | 2022-11-11 | 南京传奇生物科技有限公司 | 用于减少同种异体细胞疗法中的移植物排斥的组合物和方法 |
| MX2022012792A (es) * | 2020-04-30 | 2023-02-14 | Res Institute At Nationwide Children´S Hospital | Superar la inmunosupresion con celulas nk resistentes a tgf-\03b2. |
| WO2022036150A1 (en) * | 2020-08-13 | 2022-02-17 | Sana Biotechnology, Inc. | Methods of treating sensitized patients with hypoimmunogenic cells, and associated methods and compositions |
| CN112089847B (zh) * | 2020-08-31 | 2021-05-28 | 高连如 | 一种融合pnv靶向缺血心肌血管的干细胞药物及制备方法 |
| US11459372B2 (en) | 2020-11-30 | 2022-10-04 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| WO2022144632A1 (en) | 2020-12-30 | 2022-07-07 | Crispr Therapeutics Ag | Compositions and methods for differentiating stem cells into nk cells |
| WO2022144855A1 (en) | 2020-12-31 | 2022-07-07 | Crispr Therapeutics Ag | Universal donor cells |
| CN112972681B (zh) * | 2021-01-27 | 2022-06-07 | 西安交通大学 | Mt-nd6作为新靶点在代谢综合征诊断和治疗药物中的应用 |
| CN115124625B (zh) * | 2021-03-24 | 2024-11-26 | 圣安生医股份有限公司 | 免疫调节及抗肿瘤相关纳米抗体、其核酸编码序列及应用 |
| EP4329825A4 (en) * | 2021-04-26 | 2025-03-26 | President and Fellows of Harvard College | CD47 COMPOSITIONS AND METHODS FOR THE TREATMENT OF DEGENERATIVE EYE DISEASES |
| WO2022269393A1 (en) * | 2021-06-23 | 2022-12-29 | Crispr Therapeutics Ag | Engineered cells with improved protection from natural killer cell killing |
| US20240358855A1 (en) * | 2021-08-18 | 2024-10-31 | University Of Utah Research Foundation | Multigene constructs for treatment of age-related macular degeneration and other complement dysregulation-related conditions |
| WO2023098729A1 (en) * | 2021-11-30 | 2023-06-08 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animal with human or chimeric genes |
| KR102803344B1 (ko) * | 2022-01-19 | 2025-05-07 | 고려대학교 산학협력단 | Mfg-e8의 활성 제어를 통한 전능성 줄기세포의 선택적 세포사멸 유도 |
| EP4493275A4 (en) * | 2022-03-18 | 2026-01-21 | Memorial Sloan Kettering Cancer Center | METHODS AND COMPOSITIONS FOR IMPROVING THE IN VIVO SURVIVAL OF MESSENCEBAL DOPAMINERGIC NEURONS |
| WO2024012420A1 (zh) * | 2022-07-11 | 2024-01-18 | 士泽生物医药（苏州）有限公司 | 一种表达faslg的通用型细胞及其制备方法 |
| WO2024091959A1 (en) * | 2022-10-24 | 2024-05-02 | The Regents Of The University Of California | Drug resistant immune cells |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
| CN116785312B (zh) * | 2023-06-21 | 2023-11-14 | 天津医科大学眼科医院 | miR-15a-5p在治疗眼底疾病中的应用 |
| CN119055769B (zh) * | 2023-08-17 | 2025-09-05 | 南方医科大学南方医院 | 抗血管生成药物在提高软组织移植物保留率中的应用 |
| WO2025064604A2 (en) * | 2023-09-19 | 2025-03-27 | Musc Foundation For Research Development | Combination engineered cell therapy |
| WO2025106557A1 (en) * | 2023-11-13 | 2025-05-22 | Bluerock Therapeutics Lp | Genetically modified cells for enhanced immune evasion in allogeneic cellular therapies |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002250333A1 (en) * | 2001-03-13 | 2002-09-24 | Johns Hopkins University School Of Medicine | Fas ligand-expressing hematopoietic cells for transplantation |
| WO2006091773A2 (en) * | 2005-02-25 | 2006-08-31 | University Of Chicago | Compositions and methods related to serpin spi6 |
| DK1957633T3 (en) * | 2005-10-13 | 2014-03-17 | Anthrogenesis Corp | Immunomodulation USING PLACE SPEECH STEM CELLS |
| US20120052003A9 (en) | 2008-05-16 | 2012-03-01 | Szalay Aladar A | Microorganisms for preventing and treating neoplasms accompanying cellular therapy |
| EP2547328B1 (en) * | 2010-02-11 | 2017-06-07 | Ecole Polytechnique Fédérale de Lausanne (EPFL) | Ccr7 ligand delivery and co-delivery in immunotherapy |
| JP6285923B2 (ja) * | 2012-06-22 | 2018-02-28 | トラスティーズ・オブ・ダートマス・カレッジ | 新規ＶＩＳＴＡ−Ｉｇコンストラクト及び自己免疫、アレルギー性及び炎症性障害の処置のためのＶＩＳＴＡ−Ｉｇの使用 |
| SG11201500799YA (en) * | 2012-07-31 | 2015-03-30 | Basil M Hantash | Hla g-modified cells and methods |
| EP3021942A4 (en) * | 2013-07-19 | 2017-04-19 | The Regents of The University of California | Milk fat globule epidermal growth factor 8 regulates fatty acid uptake |
| WO2015195531A2 (en) | 2014-06-18 | 2015-12-23 | Albert Einstein College Of Medicine, Inc. | Syntac polypeptides and uses thereof |
| US11319555B2 (en) * | 2014-11-20 | 2022-05-03 | Duke University | Compositions, systems and methods for cell therapy |
| HUE064960T2 (hu) * | 2014-12-05 | 2024-04-28 | Regeneron Pharma | Differenciációs 47 gén humanizált klasztert tartalmazó nem-humán állatok |
| HUE055500T2 (hu) | 2015-03-09 | 2021-11-29 | Sinai Health Sys | Eszközök és módszerek a sejtdivíciós loci használatára a sejtek szaporodásának szabályozására |
| AU2016243128A1 (en) * | 2015-03-27 | 2017-11-02 | University Of Southern California | HLA-G as a novel target for CAR T-cell immunotherapy |
| CN107921148A (zh) | 2015-05-08 | 2018-04-17 | 哈佛学院校长同事会 | 通用供体干细胞和相关方法 |
| US11207393B2 (en) * | 2015-10-16 | 2021-12-28 | President And Fellows Of Harvard College | Regulatory T cell PD-1 modulation for regulating T cell effector immune responses |
| JP2020505025A (ja) | 2017-01-13 | 2020-02-20 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 免疫工学的な改変をした多能性細胞 |
| JP7728747B2 (ja) | 2019-08-23 | 2025-08-25 | サナ バイオテクノロジー，インコーポレイテッド | Ｃｄ２４発現細胞およびそれらの用途 |
-
2018
- 2018-06-12 IL IL270835A patent/IL270835B2/en unknown
- 2018-06-12 CN CN202510144417.3A patent/CN120041380A/zh active Pending
- 2018-06-12 KR KR1020207000550A patent/KR102738427B1/ko active Active
- 2018-06-12 CA CA3064297A patent/CA3064297A1/en active Pending
- 2018-06-12 US US16/621,490 patent/US20210161971A1/en not_active Abandoned
- 2018-06-12 IL IL314638A patent/IL314638A/en unknown
- 2018-06-12 EP EP18818206.7A patent/EP3638258A4/en active Pending
- 2018-06-12 AU AU2018285972A patent/AU2018285972B2/en active Active
- 2018-06-12 JP JP2020518110A patent/JP7391016B2/ja active Active
- 2018-06-12 KR KR1020247039926A patent/KR20250005439A/ko active Pending
- 2018-06-12 GB GB1917408.5A patent/GB2588249B/en active Active
- 2018-06-12 WO PCT/CA2018/050706 patent/WO2018227286A1/en not_active Ceased
- 2018-06-12 CN CN201880038734.5A patent/CN110869494B/zh active Active
-
2023
- 2023-02-27 US US18/175,409 patent/US12178835B2/en active Active
- 2023-06-15 AU AU2023203759A patent/AU2023203759B2/en active Active
- 2023-11-21 JP JP2023197046A patent/JP7724834B2/ja active Active
-
2024
- 2024-11-15 US US18/949,799 patent/US20250144154A1/en active Pending
-
2025
- 2025-08-05 JP JP2025130460A patent/JP2025163187A/ja active Pending
- 2025-08-18 AU AU2025217410A patent/AU2025217410A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020523037A5 (https=) | ||
| JP2024026125A5 (https=) | ||
| GB2588249A (en) | Allograft tolerance without the need for systemic immune suppression | |
| EP3471743B1 (en) | Strategies to assess and/or produce cell populations with predictive engraftment potential | |
| AU2011377617B2 (en) | Improved gene therapy methods | |
| US20190184035A1 (en) | Bcl11a homing endonuclease variants, compositions, and methods of use | |
| RU2205029C2 (ru) | Генетически измененные клетки и их применение для профилактики или лечения заболеваний | |
| IL308706A (en) | Compositions and methods for the treatment of hemoglobinopathies | |
| JP2004519245A (ja) | 肝臓細胞の増殖方法、該方法により得られる肝臓細胞、およびその用途 | |
| JP6861438B2 (ja) | Ｅｔｓ転写因子を発現する改変内皮細胞 | |
| JP2006505266A (ja) | 幹細胞の増幅因子 | |
| Brenner | Gene marking | |
| Conget et al. | Identification of a discrete population of human bone marrow-derived mesenchymal cells exhibiting properties of uncommitted progenitors | |
| JP2004505620A (ja) | 動静脈特性の操作 | |
| JP7150233B2 (ja) | 多能性幹細胞を用いた自殺遺伝子脳腫瘍治療薬 | |
| WO2005001042A2 (en) | Smooth muscle progenitor cells | |
| JP4834291B2 (ja) | Ｓｔａｔ３活性化幹細胞 | |
| Migliaccio et al. | In vivo expansion of purified hematopoietic stem cells transplanted in nonablated W/Wv mice | |
| JP7807756B2 (ja) | 所望の特異性を有するエフェクター細胞の製造方法 | |
| CN114514315B (zh) | 产自尿液细胞的内皮和平滑肌样组织及其相关用途 | |
| Kobayashi et al. | A reversibly immortalized human hepatocyte cell line as a source of hepatocyte‐based biological support | |
| CN118843688A (zh) | 低免疫原性干细胞、由干细胞分化或衍生的低免疫原性细胞及其制备方法 | |
| WO2001048150A1 (en) | Cells capable of differentiating into heart muscle cells | |
| Lanza et al. | Long-term bovine hematopoietic engraftment with clone-derived stem cells | |
| KR20070060721A (ko) | 히레귤린 베타1의 ｅｇｆ-성 도메인 펩타이드를 암호화하는ｄｎａ 서열을 포함하는 재조합 아데노바이러스 및 이를포함하는 신경세포 분화 및 재생용 약학 조성물 |